search
Back to results

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

Primary Purpose

Atrial Fibrillation (AF), Stroke

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Abelacimab
Rivaroxaban
Sponsored by
Anthos Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Atrial Fibrillation (AF) focused on measuring randomized, prospective, blinded endpoint evaluation, abelacimab, MAA868, rivaroxaban, atrial fibrillation, Factor XI, stroke, bleeding events, anti-coagulant, anticoagulation therapy

Eligibility Criteria

55 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients ≥ 55 years old
  • Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation

  • Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following:

    1. Planned concomitant use of antiplatelet medication use (i.e., aspirin and/or P2Y12 inhibitor) for the duration of the trial
    2. Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation

Exclusion Criteria:

  • History of hypersensitivity to any of the study drugs (including rivaroxaban) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for rivaroxaban
  • Patients with an intracranial or intraocular bleed within the 3 months prior to screening
  • Clinically significant mitral stenosis (valve area <1.5 cm2)
  • Mechanical heart valve or other indication for anticoagulation therapy other than atrial fibrillation (e.g., venous thromboembolism)
  • Known presence of an atrial myxoma or left ventricular thrombus
  • History of left atrial appendage closure or removal
  • Active endocarditis

Other protocol defined Inclusion/Exclusion criteria may apply

Sites / Locations

  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site (4002)
  • Anthos Investigative Site (4003)
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site
  • Anthos Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Abelacimab (MAA868)

Rivaroxaban

Arm Description

Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly

Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily.

Outcomes

Primary Outcome Measures

Evaluate effect of abelacimab relative to rivaroxaban on the rate of major or clinically relevant non-major (CRNM) bleeding events
Time to first event of composite of International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding or CRNM bleeding events

Secondary Outcome Measures

Evaluate effect of abelacimab relative to rivaroxaban on the rate of major bleeding events
Time to first event ISTH-defined major bleeding events
Evaluate the effect of abelacimab relative to rivaroxaban on the rate of major or minor bleeding events
Time to first event ISTH-defined major or minor bleeding events

Full Information

First Posted
February 11, 2021
Last Updated
January 25, 2023
Sponsor
Anthos Therapeutics, Inc.
Collaborators
The TIMI Study Group, Laboratory Corporation of America
search

1. Study Identification

Unique Protocol Identification Number
NCT04755283
Brief Title
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Acronym
AZALEA-TIMI 71
Official Title
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 2, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Anthos Therapeutics, Inc.
Collaborators
The TIMI Study Group, Laboratory Corporation of America

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation (AF), Stroke
Keywords
randomized, prospective, blinded endpoint evaluation, abelacimab, MAA868, rivaroxaban, atrial fibrillation, Factor XI, stroke, bleeding events, anti-coagulant, anticoagulation therapy

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
This is an event-driven, randomized, active-controlled, blinded endpoint, parallel-group study to evaluate the effect of two blinded doses of abelacimab relative to open-label rivaroxaban on the rate of major or clinically relevant non-major (CRNM) bleeding events in patients with atrial fibrillation (AF) who are at moderate-to-high risk of stroke.
Masking
ParticipantCare ProviderInvestigator
Masking Description
All care providers are blinded with the exception of the pharmacist and study team member assigned to administer the subcutaneous injection of abelacimab.
Allocation
Randomized
Enrollment
1200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Abelacimab (MAA868)
Arm Type
Experimental
Arm Description
Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly
Arm Title
Rivaroxaban
Arm Type
Active Comparator
Arm Description
Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily.
Intervention Type
Biological
Intervention Name(s)
Abelacimab
Other Intervention Name(s)
MAA868
Intervention Description
Abelacimab provided as liquid in vial (150 mg/mL)
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban
Intervention Description
Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
Primary Outcome Measure Information:
Title
Evaluate effect of abelacimab relative to rivaroxaban on the rate of major or clinically relevant non-major (CRNM) bleeding events
Description
Time to first event of composite of International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding or CRNM bleeding events
Time Frame
From randomization through study completion, an average of 17 months
Secondary Outcome Measure Information:
Title
Evaluate effect of abelacimab relative to rivaroxaban on the rate of major bleeding events
Description
Time to first event ISTH-defined major bleeding events
Time Frame
From randomization through study completion, an average of 17 months
Title
Evaluate the effect of abelacimab relative to rivaroxaban on the rate of major or minor bleeding events
Description
Time to first event ISTH-defined major or minor bleeding events
Time Frame
From randomization through study completion, an average of 17 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients ≥ 55 years old Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following: Planned concomitant use of antiplatelet medication use (i.e., aspirin and/or P2Y12 inhibitor) for the duration of the trial Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation Exclusion Criteria: History of hypersensitivity to any of the study drugs (including rivaroxaban) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for rivaroxaban Patients with an intracranial or intraocular bleed within the 3 months prior to screening Clinically significant mitral stenosis (valve area <1.5 cm2) Mechanical heart valve or other indication for anticoagulation therapy other than atrial fibrillation (e.g., venous thromboembolism) Known presence of an atrial myxoma or left ventricular thrombus History of left atrial appendage closure or removal Active endocarditis Other protocol defined Inclusion/Exclusion criteria may apply
Facility Information:
Facility Name
Anthos Investigative Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Anthos Investigative Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Anthos Investigative Site
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Facility Name
Anthos Investigative Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Anthos Investigative Site
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32114-2321
Country
United States
Facility Name
Anthos Investigative Site
City
Largo
State/Province
Florida
ZIP/Postal Code
33777
Country
United States
Facility Name
Anthos Investigative Site
City
Safety Harbor
State/Province
Florida
ZIP/Postal Code
34695
Country
United States
Facility Name
Anthos Investigative Site
City
Saint Augustine
State/Province
Florida
ZIP/Postal Code
32086
Country
United States
Facility Name
Anthos Investigative Site
City
Johns Creek
State/Province
Georgia
ZIP/Postal Code
30024
Country
United States
Facility Name
Anthos Investigative Site
City
Owensboro
State/Province
Kentucky
ZIP/Postal Code
42303
Country
United States
Facility Name
Anthos Investigative Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229-5222
Country
United States
Facility Name
Anthos Investigative Site
City
Salisbury
State/Province
Maryland
ZIP/Postal Code
21804
Country
United States
Facility Name
Anthos Investigative Site
City
Framingham
State/Province
Massachusetts
ZIP/Postal Code
01701
Country
United States
Facility Name
Anthos Investigative Site
City
Haverhill
State/Province
Massachusetts
ZIP/Postal Code
01830
Country
United States
Facility Name
Anthos Investigative Site
City
Lansing
State/Province
Michigan
ZIP/Postal Code
48912
Country
United States
Facility Name
Anthos Investigative Site
City
Sewell
State/Province
New Jersey
ZIP/Postal Code
08080
Country
United States
Facility Name
Anthos Investigative Site
City
Poughkeepsie
State/Province
New York
ZIP/Postal Code
12601
Country
United States
Facility Name
Anthos Investigative Site
City
Southampton
State/Province
New York
ZIP/Postal Code
11968
Country
United States
Facility Name
Anthos Investigative Site
City
Lenoir
State/Province
North Carolina
ZIP/Postal Code
28645
Country
United States
Facility Name
Anthos Investigative Site
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58104
Country
United States
Facility Name
Anthos Investigative Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73135
Country
United States
Facility Name
Anthos Investigative Site
City
Camp Hill
State/Province
Pennsylvania
ZIP/Postal Code
17011
Country
United States
Facility Name
Anthos Investigative Site
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Anthos Investigative Site
City
Kingwood
State/Province
Texas
ZIP/Postal Code
77339
Country
United States
Facility Name
Anthos Investigative Site
City
Odessa
State/Province
Texas
ZIP/Postal Code
79761-5133
Country
United States
Facility Name
Anthos Investigative Site
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Anthos Investigative Site
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Facility Name
Anthos Investigative Site
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20109
Country
United States
Facility Name
Anthos Investigative Site
City
New Westminster
State/Province
British Columbia
ZIP/Postal Code
V3L 3W5
Country
Canada
Facility Name
Anthos Investigative Site
City
Cambridge
State/Province
Ontario
ZIP/Postal Code
N1R 7R1
Country
Canada
Facility Name
Anthos Investigative Site
City
Oshawa
State/Province
Ontario
ZIP/Postal Code
L1J2K1
Country
Canada
Facility Name
Anthos Investigative Site
City
Sudbury
State/Province
Ontario
ZIP/Postal Code
P3B 4H5
Country
Canada
Facility Name
Anthos Investigative Site
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2G8
Country
Canada
Facility Name
Anthos Investigative Site
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T 3Y7
Country
Canada
Facility Name
Anthos Investigative Site
City
Mariánské Lázně
State/Province
KA
ZIP/Postal Code
353 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Trutnov
State/Province
KR
ZIP/Postal Code
541 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Liberec
State/Province
LB
ZIP/Postal Code
460 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Liberec
State/Province
LI
ZIP/Postal Code
460 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Česká Lípa
State/Province
LI
ZIP/Postal Code
470 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Pardubice
State/Province
PA
ZIP/Postal Code
530 02
Country
Czechia
Facility Name
Anthos Investigative Site
City
Praha
State/Province
PR
ZIP/Postal Code
10100
Country
Czechia
Facility Name
Anthos Investigative Site
City
Praha
State/Province
PR
ZIP/Postal Code
110 00
Country
Czechia
Facility Name
Anthos Investigative Site
City
Praha
State/Province
PR
ZIP/Postal Code
158 00
Country
Czechia
Facility Name
Anthos Investigative Site
City
Brandýs Nad Labem
State/Province
Středočeský Kraj
ZIP/Postal Code
250 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Poděbrady
State/Province
Středočeský Kraj
ZIP/Postal Code
29001
Country
Czechia
Facility Name
Anthos Investigative Site
City
Příbram
State/Province
Středočeský Kraj
ZIP/Postal Code
261 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Slaný
State/Province
Středočeský Kraj
ZIP/Postal Code
274 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Kroměříž
State/Province
ZL
ZIP/Postal Code
767 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Holešov
State/Province
Zlín
ZIP/Postal Code
769 01
Country
Czechia
Facility Name
Anthos Investigative Site
City
Orosháza
State/Province
BE
ZIP/Postal Code
5900
Country
Hungary
Facility Name
Anthos Investigative Site
City
Baja
State/Province
BK
ZIP/Postal Code
6500
Country
Hungary
Facility Name
Anthos Investigative Site
City
Budapest
State/Province
BP
ZIP/Postal Code
1036
Country
Hungary
Facility Name
Anthos Investigative Site
City
Budapest
State/Province
BP
ZIP/Postal Code
1122
Country
Hungary
Facility Name
Anthos Investigative Site
City
Budapest
State/Province
BU
ZIP/Postal Code
1033
Country
Hungary
Facility Name
Anthos Investigative Site
City
Budapest
State/Province
BU
ZIP/Postal Code
1134
Country
Hungary
Facility Name
Anthos Investigative Site
City
Székesfehérvár
State/Province
FE
ZIP/Postal Code
8000
Country
Hungary
Facility Name
Anthos Investigative Site
City
Debrecen
State/Province
HB
ZIP/Postal Code
4025
Country
Hungary
Facility Name
Anthos Investigative Site
City
Kaposvár
State/Province
SO
ZIP/Postal Code
7400
Country
Hungary
Facility Name
Anthos Investigative Site (4002)
City
Nyíregyháza
State/Province
SZ
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Anthos Investigative Site (4003)
City
Nyíregyháza
State/Province
SZ
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Anthos Investigative Site
City
Balatonfüred
State/Province
VE
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Anthos Investigative Site
City
Balatonfüred
State/Province
VM
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Anthos Investigative Site
City
Seogu
State/Province
Busan
ZIP/Postal Code
49201
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Seongnam-si
State/Province
Gyeonggi
ZIP/Postal Code
13496
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Seongnam-si
State/Province
Gyeonggi
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Seoul
ZIP/Postal Code
158-710
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Seoul
ZIP/Postal Code
3080
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Seoul
ZIP/Postal Code
3722
Country
Korea, Republic of
Facility Name
Anthos Investigative Site
City
Wrocław
State/Province
DS
ZIP/Postal Code
51-162
Country
Poland
Facility Name
Anthos Investigative Site
City
Żarów
State/Province
DS
ZIP/Postal Code
58-130
Country
Poland
Facility Name
Anthos Investigative Site
City
Gdynia
State/Province
GDY
ZIP/Postal Code
81-423
Country
Poland
Facility Name
Anthos Investigative Site
City
Zamość
State/Province
LB
ZIP/Postal Code
22-400
Country
Poland
Facility Name
Anthos Investigative Site
City
Łódź
State/Province
LD
ZIP/Postal Code
92-213
Country
Poland
Facility Name
Anthos Investigative Site
City
Lublin
State/Province
LU
ZIP/Postal Code
20-001
Country
Poland
Facility Name
Anthos Investigative Site
City
Chrzanów
State/Province
MA
ZIP/Postal Code
32-500
Country
Poland
Facility Name
Anthos Investigative Site
City
Kraków
State/Province
MA
ZIP/Postal Code
31-202
Country
Poland
Facility Name
Anthos Investigative Site
City
Płock
State/Province
MZ
ZIP/Postal Code
09-402
Country
Poland
Facility Name
Anthos Investigative Site
City
Warsaw
State/Province
MZ
ZIP/Postal Code
02-097
Country
Poland
Facility Name
Anthos Investigative Site
City
Warszawa
State/Province
MZ
ZIP/Postal Code
04-628
Country
Poland
Facility Name
Anthos Investigative Site
City
Przemyśl
State/Province
PK
ZIP/Postal Code
05-825
Country
Poland
Facility Name
Anthos Investigative Site
City
Przemyśl
State/Province
PK
ZIP/Postal Code
37-700
Country
Poland
Facility Name
Anthos Investigative Site
City
Gdynia
State/Province
PM
ZIP/Postal Code
81-157
Country
Poland
Facility Name
Anthos Investigative Site
City
Bielsko-Biala
State/Province
SL
ZIP/Postal Code
43-316
Country
Poland
Facility Name
Anthos Investigative Site
City
Dąbrowa Górnicza
State/Province
SL
ZIP/Postal Code
41-300
Country
Poland
Facility Name
Anthos Investigative Site
City
Ruda Śląska
State/Province
SL
ZIP/Postal Code
41-710
Country
Poland
Facility Name
Anthos Investigative Site
City
Tychy
State/Province
SL
ZIP/Postal Code
43-100
Country
Poland
Facility Name
Anthos Investigative Site
City
Elbląg
State/Province
WN
ZIP/Postal Code
82-300
Country
Poland
Facility Name
Anthos Investigative Site
City
Taipei
State/Province
HSZ
ZIP/Postal Code
30071
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Hualien City
State/Province
HUA
ZIP/Postal Code
970
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Yilan
State/Province
ILA
ZIP/Postal Code
26058
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Kaohsiung
State/Province
KHH
ZIP/Postal Code
807
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Taipei City
State/Province
TPE
ZIP/Postal Code
116
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Taipei
State/Province
TPE
ZIP/Postal Code
11217
Country
Taiwan
Facility Name
Anthos Investigative Site
City
Tiachung
State/Province
TXG
ZIP/Postal Code
404
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

We'll reach out to this number within 24 hrs